CANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment

Stock News12-19

CANSINOBIO (06185) announced that its self-developed combined vaccine, DTcP-Hib-MCV4 (adsorbed acellular pertussis [component], diphtheria, tetanus, Haemophilus influenzae type b [conjugate], and ACYW135 meningococcal polysaccharide [conjugate] combined vaccine), has officially commenced Phase I clinical trials, with the first subject successfully enrolled.

Aligned with the company's product pipeline strategy and market demand for multivalent vaccines, CANSINOBIO aims to develop the DTcP-Hib-MCV4 combined vaccine to establish differentiated competitiveness. The Phase I trial will evaluate the safety and immunogenicity of the vaccine in subjects aged 2 months to 6 years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181903035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181903035","market":"nz","top_or_hot":-1,"title":"CANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment","media":"Stock News","content":"<p>CANSINOBIO (06185) announced that its self-developed combined vaccine, DTcP-Hib-MCV4 (adsorbed acellular pertussis [component], diphtheria, tetanus, Haemophilus influenzae type b [conjugate], and ACYW135 meningococcal polysaccharide [conjugate] combined vaccine), has officially commenced Phase I clinical trials, with the first subject successfully enrolled.</p>\n<p>Aligned with the company's product pipeline strategy and market demand for multivalent vaccines, CANSINOBIO aims to develop the DTcP-Hib-MCV4 combined vaccine to establish differentiated competitiveness. The Phase I trial will evaluate the safety and immunogenicity of the vaccine in subjects aged 2 months to 6 years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-19 16:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) announced that its self-developed combined vaccine, DTcP-Hib-MCV4 (adsorbed acellular pertussis [component], diphtheria, tetanus, Haemophilus influenzae type b [conjugate], and ACYW135 meningococcal polysaccharide [conjugate] combined vaccine), has officially commenced Phase I clinical trials, with the first subject successfully enrolled.</p>\n<p>Aligned with the company's product pipeline strategy and market demand for multivalent vaccines, CANSINOBIO aims to develop the DTcP-Hib-MCV4 combined vaccine to establish differentiated competitiveness. The Phase I trial will evaluate the safety and immunogenicity of the vaccine in subjects aged 2 months to 6 years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1181903035","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181903035","pubTimestamp":1766133372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) announced that its self-developed combined vaccine, DTcP-Hib-MCV4 (adsorbed acellular pertussis [component], diphtheria, tetanus, Haemophilus influenzae type b [conjugate], and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物","BK1191":"制药","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"康希诺生物(06185)启动DTcP-Hib-MCV4联合疫苗I期临床试验并完成首例受试者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO (06185) announced that its self-developed combined vaccine, DTcP-Hib-MCV4 (adsorbed acellular pertussis [component], diphtheria, tetanus, Haemophilus influenzae type b [conjugate], and ACYW135 meningococcal polysaccharide [conjugate] combined vaccine), has officially commenced Phase I clinical trials, with the first subject successfully enrolled.\nAligned with the company's product pipeline strategy and market demand for multivalent vaccines, CANSINOBIO aims to develop the DTcP-Hib-MCV4 combined vaccine to establish differentiated competitiveness. The Phase I trial will evaluate the safety and immunogenicity of the vaccine in subjects aged 2 months to 6 years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181903035","isCrawlerRequest":true}